Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Sep 18, 2020 10:35am
126 Views
Post# 31580826

Corporate Update

Corporate UpdateThey took away there fact sheet updated in August replaced today with Corportate update this month. A little messy, fact sheet was always a two pager, last one showed by the end of Sept/ 3rd quarter Alzheimer's and Serology assays. Now 50 pages of two presentations in fact sheet corporate update totally messed up!!!!! 

Last September 2019 at the same HC Wainwright conference, Summary Investment Thesis, Near term (3-12 month) value creation through partnering deals. Numerous examples of preclinical partnerning deals for assets in Promis areas, $50MM +/- up-front total milestones $500MM-$700MM. Promis in active discussions with potential large pharma partners for multiple assets.

Have noticed partnering is mentioned less and less, the 3-12 months are up with no deals...
Bullboard Posts